|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0024301,
umls-concept:C0034897,
umls-concept:C0086045,
umls-concept:C0087111,
umls-concept:C0229671,
umls-concept:C0295415,
umls-concept:C0393022,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1999-2-4
|
|
pubmed:abstractText |
Monoclonal antibodies are being utilized for treatment of patients with low-grade non-Hodgkin's lymphoma as well as other cancers. Results from phase I and II clinical studies has shown that the chimeric monoclonal antibody Rituximab has minimal toxicity and significant therapeutic activity in low grade non-Hodgkin's lymphoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
995-1001
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9818074-Antibodies, Monoclonal,
pubmed-meshheading:9818074-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:9818074-Antineoplastic Agents,
pubmed-meshheading:9818074-Half-Life,
pubmed-meshheading:9818074-Humans,
pubmed-meshheading:9818074-Immunoglobulins, Intravenous,
pubmed-meshheading:9818074-Lymphoma, Follicular,
pubmed-meshheading:9818074-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9818074-Neoplasm Recurrence, Local,
pubmed-meshheading:9818074-Treatment Outcome
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Department of Medicine, Toronto-Sunnybrook Regional Cancer Centre, Ontario, Canada. neil.berinstein@utoronto.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase III
|
